Governance & advisory boards

Management and Governing Board Members

The Governing Board is the official management body of the network responsible for network-wide decision making. It consists of one representative from each partner organisation and meets twice a year.

TREAT-NMD Governing Board

Scientific Representative
Partner Organisation
Volker Straub/Kate Bushby Newcastle University, UK (Chair)
Christophe Béroud INSERM, France
Annemieke Aartsma-Rus Leiden University Medical Center, Netherlands
Rudolf Korinthenberg MD-NET, Germany
Veronica Karcagi National Institure of Environmental Health, Hungary
Francesco Muntoni/Richard Hughes University College London, UK
Annette Boersen European Neuromuscular Centre, Netherlands
Serge Braun/Thomas Voit AFM, France
Markus Ruegg University of Basel, Switzerland
Fabrizia Bignami EURORDIS
Thomas Sejersen Karolinska Institute, Sweden
Michael Rose Kings College London, UK
Thomas Meier/Stefanie Possekel Santhera Pharmaceuticals, Switzerland
Carina Wallgren-Pettersson Helsinki University, Finland
Kay Davies Medical Research Council, UK
Anna Ambrosini Fondazione Telethon, Italy
Peter Van den Bergh Universite Catholique de Louvain, Belgium
Miguel Chillón Universitat Autonoma de Barcelona, Spain
Muriel Audit Genosafe
Loic Courtot ACIES

 

The Governing Board is supported by the following Advisory Bodies:

Scientific and Technological Advisory Council (STAC)

Intellectual Property Use and Dissemination Committee (IPUDC)

Industrial Liaison Council (ILC)

Project Ethics Council (PEC)

Related Images

 


TREAT-NMD Coordination Office: T: +44 191 241 8605 Fax: +44 191 241 8770 E:
FP6 Logo TREAT-NMD is supported through Priority 1 (Life Sciences, Genomics and Biotechnology for Health) of the European Union’s FP6 under contract number LSHM-CT-2006-036825 EU flag